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Summary Statement: 32 
Lgr5 positive bipotent hepatoblasts contribute to liver development and reside at the apex of 33 





During mouse embryogenesis, progenitors within the liver known as hepatoblasts give rise to 39 
adult hepatocytes and cholangiocytes. Hepatoblasts, which are specified at E8.5-E9.0, have 40 
been regarded as a homogeneous progenitor population that initiate differentiation from E13.5. 41 
Recently, scRNA-seq analysis has identified sub-populations of transcriptionally distinct 42 
hepatoblasts at E11.5. Here we show that hepatoblasts are not only transcriptionally but also 43 
functionally heterogeneous, and that a sub-population of E9.5-E10.0 hepatoblasts exhibit a 44 
previously unidentified early-commitment to cholangiocyte fate. Importantly, we also identify 45 
a sub-population constituting 2% of E9.5-E10.0 hepatoblasts that express the adult stem cell 46 
marker Lgr5, and generate both hepatocyte and cholangiocyte progeny that persist for the life-47 
span of the mouse. Combining lineage tracing and scRNA-seq, we show that Lgr5 marks E9.5-48 
E10.0 bipotent liver progenitors residing at the apex of a hepatoblast hierarchy. Notably, 49 
isolated Lgr5+ hepatoblasts can be clonally expanded in vitro into embryonic liver organoids, 50 
which can commit to either hepatocyte or cholangiocyte fates. Our study demonstrates 51 
functional heterogeneity within E9.5 hepatoblasts and identifies Lgr5 as a marker for a sub-52 
population of bipotent liver progenitors.   53 
 3 
Introduction 54 
The liver is composed predominantly of hepatocytes and cholangiocytes (also known as ductal 55 
cells or biliary epithelial cells (BECs)). These epithelial cells work in conjunction with the liver 56 
stromal, endothelial and mesenchymal cells to perform essential metabolic, exocrine and 57 
endocrine functions (Zorn, 2008). In addition, epithelial cells have a tremendous capacity for 58 
liver regeneration, which is vital given the constant exposure of the liver to metabolic and toxic 59 
substances. 60 
During mouse embryogenesis, liver specification from the ventral foregut endoderm begins at 61 
embryonic day (E)8.5 followed by the formation of the hepatic diverticulum. Circa E9.5, 62 
hepatic endoderm cells, termed hepatoblasts, proliferate, delaminate and migrate into the 63 
adjacent septum transversum mesenchyme (STM) to form the liver bud. Hepatoblasts are the 64 
embryonic progenitors for adult hepatocytes and cholangiocytes, whilst the STM contributes 65 
to the prospective hepatic mesenchyme (Medlock and Haar, 1983; Zorn, 2008). The STM and 66 
hepatic mesenchyme secrete several growth factors including FGF, BMP, HGF and Wnt, 67 
which promote hepatoblast proliferation, migration and survival (reviewed in Zorn, 68 
Stembook). Histological data at E13.5 show subsets of hepatoblasts near the portal 69 
mesenchyme upregulate biliary-specific cytokeratins, indicating that biliary differentiation is 70 
initiated by E13.5 (Germain et al., 1988; Lemaigre, 2003). By contrast, hepatoblasts that are 71 
not in contact with portal veins respond to signals from the closely associated haematopoietic 72 
cells in the liver and differentiate into hepatocytes (Zorn, 2008).  73 
Previous studies have hinted towards the bipotential nature of hepatoblasts; 74 
immunohistochemical analysis in rats showed that expression of proteins such as γ-glutamyl 75 
transpeptidase, which are detected at low levels in almost all hepatoblasts, become upregulated 76 
and restricted to differentiated cholangiocytes only and not hepatocytes (Germain et al., 1988). 77 
Similarly, hepatoblasts near the portal mesenchyme, destined to become cholangiocytes, 78 
transiently express Afp and Alb, two markers that later become restricted to hepatocytes 79 
(Shiojiri et al., 2001). These reports show that the hepatoblast population expresses markers of 80 
both hepatocytes and cholangiocytes, which later become lineage restricted. More recent 81 
studies have used positive selection with surface markers to isolate hepatoblasts before 82 
characterisation, as reviewed in (Miyajima et al., 2014). However, the processes that regulate 83 
the cholangiocyte versus hepatocyte decision remain unclear. It is also unclear whether a single 84 
hepatoblast can give rise to both cholangiocytes and hepatocytes, i.e. whether single 85 
hepatoblasts are bipotent or if there are sub-populations of unipotent hepatoblasts.  86 
 87 
During endoderm patterning, Wnt signalling represses liver fate (McLin et al., 2007), but is 88 
required at E10 for liver bud formation (Micsenyi et al., 2004) and hepatic proliferation (Tan 89 
et al., 2008). The Wnt target gene Lgr5 was originally described as an adult intestinal stem cell 90 
marker (Barker et al., 2007). Lgr5 has since been reported to be a marker of cycling adult stem 91 
cells in many other organs, such as the stomach, mammary gland and tongue, amongst others 92 
(Koo and Clevers, 2014). In the homeostatic liver, Lgr5 expression is restricted to pericentral 93 
hepatocytes (Planas-Paz et al., 2016). However, in response to damage, Lgr5 becomes highly 94 
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upregulated in the portal tract region and marks cells, which can repopulate the damaged liver 95 
(Huch et al., 2013). In the embryo, Lgr5 has been reported as a marker of bipotent progenitors 96 
in developing mammary cells (Trejo et al., 2017), kidney (Barker et al., 2012) and intestine 97 
(Kinzel et al., 2014). Bulk RNAseq analysis of embryonic tissue identified many components 98 
of the Wnt pathway, including Lgr5, to be differentially expressed in the E10.5 liver compared 99 
to the embryonic pancreas (Rodríguez-Seguel et al., 2013). Furthermore, recent single-cell 100 
RNA sequencing (scRNA-seq) analysis of E11.5 livers reported that the embryonic liver 101 
harbours sub-populations of transcriptionally heterogeneous hepatoblasts, some of which 102 
express Lgr5 (Yang et al., 2017). However, these studies did not address whether the 103 
transcriptional heterogeneity observed reflects a genuine functional heterogeneity of the 104 
hepatoblast pool, nor did they investigate the role of Lgr5+ cells during embryonic liver 105 
development. 106 
Here, by combining multicolour clonal genetic lineage tracing, organoid cultures and scRNA-107 
seq analysis, we demonstrate that Lgr5 marks a subpopulation of bona fide bipotent 108 




Lgr5 is a marker of hepatoblasts in the E9.5 liver 112 
 113 
Lgr5 expression has been reported in the developing liver as early as E10.5 (Rodríguez-Seguel 114 
et al., 2013; Yang et al., 2017). However, these studies were performed at the RNA level and 115 
there was no functional assessment of the potentiality of Lgr5-expressing cells. To investigate 116 
whether Lgr5 marks bona fide hepatoblasts, we used a lineage tracing strategy to identify the 117 
progeny of Lgr5-expressing cells (Kretzschmar and Watt, 2012). Thus, we generated Lgr5-118 
IRES-CreERT2/R26R-TdTomato embryos where, upon tamoxifen induction, Lgr5+ cells and 119 
their progeny become labelled with TdTomato. Since hepatoblast delamination and formation 120 
of the liver bud occurs at E9.5 we first assessed whether Lgr5 is expressed within this very 121 
early hepatoblast pool. To this end, we induced E9.5 embryos with tamoxifen and collected 122 
embryos at E11.5.  We found that Lgr5 is expressed as early as E9.5-E10 (considering the time 123 
lag for tamoxifen to induce TdTomato) in the embryonic liver as we detected TdTomato+ 124 
fluorescence in the isolated livers (Fig. 1A) and determined the labelling efficiency of Lgr5+ 125 
cells to be 19.6±2.2%. We next sought to address which cell type(s) express Lgr5 during liver 126 
development. We found that, at E11.5, Lgr5+ cells labelled at E9.5 co-expressed alpha 127 
fetoprotein (AFP), a well-characterised hepatoblast marker, but did not co-express markers for 128 
the endothelial (VEGFR3) or hematopoietic (CD45) lineages (Fig. 1B,C). Although labelled 129 
cells do not express endothelial markers, we found that they are located directly adjacent to the 130 
endothelial cells (Fig. 1B) (Movie S1), suggesting that cell-cell interactions between the 131 
endothelium and hepatoblasts may serve to pattern tissue. Additionally, staining with Ki67 132 
revealed that over half of the Lgr5+ cells were proliferative (Fig. 1B,C). Collectively, these 133 
results reveal the existence of a population of proliferative Lgr5+ cells with hepatoblast features 134 
at E9.5-E10. 135 
To assess whether Lgr5+ cells are bona fide hepatoblasts, we analysed their contribution to the 136 
formation of both mature hepatocytes and cholangiocytes in the postnatal liver. We induced 137 
Lgr5-IRES-CreERT2/R26R-TdTomato embryos at E9.5 and collected postnatal livers over the 138 
course of a year (Fig. 2A). We detected TdTomato+ descendants of the initially labelled E9.5-139 
E10 Lgr5+ cells at all time-points analysed (from 1 month up to 1 year after birth) in all three 140 
functional zones of the liver (zones 1-3; Fig. 2B). Importantly, we identified both hepatocytes 141 
and cholangiocytes as descendants of the E9.5 Lgr5+ hepatoblasts (Figs. 2B,S1A). By contrast, 142 
induction at a later time-point (E13.5) resulted in only hepatocyte labelling at 1 month after 143 
birth indicating that, by E13.5-E14, Lgr5+ liver progenitors are committed to hepatocyte fate 144 
(Fig. S1B). Of note, induction at earlier time-points (E7.5 and E8.5) did not result in any 145 
labelled progeny in the postnatal liver (Fig. S1C) suggesting that, at this stage of embryonic 146 
development, Lgr5 marks exclusively liver progenitors after specification and liver bud 147 
formation, but not definitive endoderm or foregut progenitors that will contribute to 148 
prospective liver tissue. No labelling was detected in non-induced mice (Fig. S1D). Altogether, 149 
our lineage tracing demonstrates that Lgr5 is a bona fide hepatoblast marker for E9.5-E10 liver 150 
bud hepatic progenitors with the capacity to give rise to adult hepatocytes and cholangiocytes. 151 
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Lgr5 marks bona fide bipotent hepatoblasts at the earliest stage of embryonic liver 152 
development 153 
 154 
To date, it has been unclear whether hepatoblasts are bipotent, i.e. that a single hepatoblast can 155 
give rise to both cholangiocytes and hepatocytes, or are unipotent, implying the co-existence 156 
of progenitors restricted to either hepatocyte-only or cholangiocyte-only fate. To assess 157 
whether E9.5-E10 Lgr5+ hepatoblasts are bipotent, we turned to a clonal lineage tracing 158 
strategy to determine the contribution of each marked cell to a given fate. To mitigate the 159 
effects of cell dispersion during development, we opted to use a multicolour lineage tracing 160 
approach, where clones derived from single cells are labelled with different colours. Lineage 161 
tracing with the R26R-Confetti reporter (Snippert et al., 2010) in combination with the Lgr5-162 
IRES-CreERT2 allele results in stochastic labelling of Lgr5+ cells with either RFP, YFP, GFP 163 
or CFP following induction with tamoxifen at E9.5 (Fig. 3A). As expected, we detected distinct 164 
clones labelled with one of the four fluorescent proteins at all time-points analysed (P0-P17) 165 
(Figs. 3B,S2A).  166 
 167 
Recently, we showed that, due to cell rearrangements during the expansion of developing 168 
tissues, marked cells can become dispersed and clones “fragmented”, with the potential to 169 
confound the interpretation of labelling data during development (Rulands et al., 2018). 170 
Therefore, to ensure that only cells within individual clones were scored, we opted to take into 171 
consideration only those clones in the portal tract labelled with a single colour where ductal 172 
cells and hepatocytes were juxtaposed. We scored 70 individual clones in this manner, 81% of 173 
which were comprised of hepatocytes only. No cholangiocyte-only clones were found. 174 
Crucially, from all clones identified, 37% were identified near a portal tract and half of these 175 
(50%) contained both labelled hepatocytes and cholangiocytes of the same Confetti-colour 176 
(Fig. 3C,D, Movie S2 and Supplementary dataset 2_S3). As, expected, we found clones in 177 
zones 2 and 3 throughout the liver formed of hepatocytes only. Clone merger, i.e. the frequency 178 
at which labelled cells with the same colour are counted as a single clone but originate from 179 
two recombination events, was estimated to be less than 3.6 ± 1.9% for all colours (Fig. S2A,B) 180 
indicating that, from the 13 bipotent clones identified, at least 12 clones are truly bipotent. As 181 
before, no labelling was detected in non-induced mice (Fig. S2C). Therefore, clonal analysis 182 
of individual Lgr5+ hepatoblasts demonstrates that, at E9.5-E10, at least some of the Lgr5 183 
expressing cell population are bipotent. 184 
 185 
Lgr5+ embryonic liver cells grow into organoids in vitro and generate both ductal and 186 
hepatocyte fated organoids 187 
 188 
Single Lgr5+ cells isolated from livers of adult mice (Huch et al., 2013) and humans (Huch et 189 
al., 2015) can be grown clonally into cholangiocyte-like liver organoids, which retain the  190 
bipotential characteristics of adult cholangiocyte progenitors, being able to self-duplicate while 191 
maintaining the capacity to differentiate into both hepatocytes and cholangiocytes in vitro. We 192 
therefore sought to assess whether Lgr5+ embryonic liver hepatoblasts could also form self-193 
renewing organoids whilst retaining their bipotential characteristics in vitro by isolating Lgr5+ 194 
hepatoblasts and placing them in culture.  195 
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 196 
Recently, further optimization of our protocols to expand human adult liver cells (Huch et al., 197 
2015) has facilitated the expansion of human embryonic (week 11-20 human gestation) liver 198 
tissue as 3D organoid cultures (Hu et al., 2018). However, the media requirements to establish 199 
mouse embryonic liver organoids have not yet been reported. Hence, we first sought to 200 
establish culture conditions that would enable the expansion of mouse organoid cultures from 201 
the embryonic liver, opting first to use whole liver tissue isolated from E10.5-E11.5 mouse 202 
embryos without selection for specific hepatoblast cells. The use of E10.5-E11.5 rather than 203 
E9.5 embryos was for practical reasons; at E9.5 the prospective liver has not yet formed a clear 204 
organ structure and therefore it was not possible to isolate liver alone, resulting in 205 
contamination from other foregut derived tissues, especially stomach (data not shown). To 206 
establish cholangiocyte-like organoids from the embryonic liver, we modified our previously 207 
published protocol to expand mouse adult ductal liver organoids (Broutier et al., 2016; Huch 208 
et al., 2013) by adding a TGFb inhibitor and Forskolin (Fig. S3A) to the medium. In parallel, 209 
to establish hepatocyte-like organoids, we adapted a recently published protocol for human 210 
embryonic liver (Hu et al., 2018) by removing FGF7 during passaging (Fig. S3B). Using these 211 
culture conditions we could expand mouse embryonic liver organoids for up to 5 passages (3 212 
months in culture) (Fig. S3C).  213 
Next, we assessed whether single Lgr5+ cells isolated from E10.5-E12.5 livers would retain 214 
their ability to differentiate into either lineage in vitro when cultured in our optimized 215 
cholangiocyte-like and hepatocyte-like media conditions. To this end, we first established a 216 
sorting strategy that would enable isolation of pure populations of Lgr5+ E10.5-E12.5 217 
hepatoblasts, utilising the Lgr5-EGFP-IRES-creERT2 mouse line, where the eGFP reporter is 218 
knocked-in into the Lgr5 locus (Barker et al., 2007), combined with co-staining with anti-Liv2, 219 
which specifically labels E9.5-E13.5 liver progenitors (Nierhoff et al., 2005; Watanabe et al., 220 
2002). We confirmed the hepatoblast characteristics of E10.5 Lgr5+ liver progenitors by co-221 
staining with anti-Liv2 (Fig. 4A). Given that the developing liver serves as the site of 222 
haematopoiesis from E10.5 until the perinatal stage (Sasaki and Sonoda, 2000), we used 223 
negative selection of the hematopoietic marker CD45 and endothelial marker CD31 to limit 224 
contamination by non-liver progenitor cells. Embryonic livers were collected at E10.5-E12.5, 225 
enzymatically digested and then fluorescence activated cell sorting (FACS) was used to isolate 226 
(Liv2+/CD31-/CD45-/Lgr5-GFP+) Lgr5+ hepatoblasts (Fig. S4). Sorted Lgr5+ cells were 227 
embedded in Matrigel (as extracellular matrix) and cultured under our two optimized media 228 
conditions (Fig. 4B). We observed that clonally derived embryonic organoids from isolated 229 
Lgr5+ hepatoblasts cultured with cholangiocyte-like medium displayed a similar expansion 230 
potential to the organoids derived from whole embryonic livers (Fig. S3C). We found that 231 
clonally derived Lgr5+ hepatoblasts cultured with hepatocyte-like medium readily form 232 
organoid structures, albeit with a lower expansion potential than those derived from whole 233 
embryonic livers (Fig. S3C). 234 
 235 
The morphology of structures generated was dependent on the culture medium used. Addition 236 
of cholangiocyte-like medium resulted in the generation of single-layered epithelial spheres 237 
(Fig. 4C). The duct-like morphology of embryonic organoids cultured with cholangiocyte-like 238 
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medium and expression of the classic cholangiocyte marker Krt19 (Figs.4E, F) is reminiscent 239 
of mouse adult ductal liver organoids (Huch et al., 2013) (Fig. S3D). Conversely, Lgr5+ cells 240 
cultured with hepatocyte-like medium developed more compact, densely budding structures 241 
(Fig. 4D) which resemble the recently published human embryonic hepatocyte organoids (Hu 242 
et al., 2018). The hepatocyte-like nature of these cultures was confirmed by high levels of Alb 243 
expression (Fig. 4E), clear detection of Hnf4a (Fig. 4F) and functionally by an increased 244 
secretion of Albumin (Fig. 4G). Embryonic organoids cultured with hepatocyte-like medium 245 
secrete more AFP than both embryonic organoids cultured with cholangiocyte-like medium 246 
and adult ductal liver organoids (Fig. 4H). This suggests that embryonic hepatocyte-like 247 
organoids retain their embryonic status more than those cultured with cholangiocyte-like 248 
medium. These results confirm that Lgr5+ hepatoblasts retain self-renewal and differentiation 249 
capacity in vitro, being capable of differentiating towards both cholangiocyte and hepatocyte 250 
fates.  251 
 252 
scRNA-seq identifies heterogeneity within the hepatoblast population 253 
 254 
To address whether all hepatoblasts express Lgr5 or whether Lgr5 is instead a marker of a 255 
specific sub-population of bona fide bipotent hepatoblasts, we performed single-cell RNA 256 
sequencing (scRNA-seq) analysis on both Lgr5+ hepatoblasts and bulk embryonic liver 257 
progenitors derived from either E10.5 or E13.5 livers. To isolate liver progenitors (Liv2+) and 258 
Lgr5+ hepatoblasts (Liv2+Lgr5+), we applied our established sorting strategy to E10.5 and 259 
E13.5 embryonic livers derived from Lgr5-EGFP-IRES-creERT2 mice (Fig. 5A). Sorted 260 
Liv2+/CD31-/CD45- cells (Liv2+ bulk hepatoblast population) and Liv2+/CD31-/CD45-/Lgr5-261 
GFP+ cells (Lgr5+ hepatoblasts) were subjected to scRNA-seq analysis based on the Smart-262 
seq2 protocol (Picelli et al., 2014). scRNA-seq analysis was conducted on 943 sorted cells. 263 
Following quality control, 653 cells progressed for further analysis. To reduce technical 264 
variability between biological replicates, we applied batch effect correction by matching 265 
mutual nearest neighbours. 266 
To define embryonic liver progenitor populations, we performed dimensionality reduction 267 
using t-distributed stochastic neighbour embedding (tSNE) analysis on all 653 cells (Fig. 5B). 268 
This identified three distinct progenitor populations, which were confirmed by Louvain 269 
clustering. These three clusters signified biological differences, since each cluster contained 270 
cells from each biological replicate. The biological differences were confirmed by the 271 
expression of distinct marker genes (Figs. 5B, S5A and Supplementary dataset 1). The cell type 272 
identity of each cluster was assigned based on examining marker genes and comparing them 273 
to publicly available gene expression patterns in human or mouse liver (Broutier et al., 2017; 274 
Yang et al., 2017). We found that the three clusters corresponded to proliferating hepatoblasts 275 
(HB), hepatocyte-like progenitors (Hep) and cholangiocyte-like progenitors (Chol), which 276 
express higher levels of representative markers. The HB cluster contained Id3, Mdk and Gpc3, 277 
all described as hepatoblast markers (Su et al., 2017; Yang et al., 2017), while the Hep cluster 278 
contained Ttr, Alb, Apoa1, Apoa2 and C3, all known hepatocyte markers, and the Chol cluster 279 
expressed the ductal cell genes Car2, Cd44 and Bcl11a (Yang et al., 2017) (Fig. 5B and 280 
Supplementary dataset 1_S1-S7). Of note, within the E10.5 Chol cluster we found two sub-281 
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clusters (Supplementary dataset 1_S7). As well as identifying known cholangiocyte and 282 
hepatocyte markers, new markers for these clusters were also revealed by our analysis (Fig. 283 
S5A and Supplementary dataset 1_S1-S7).  284 
 285 
To establish developmental trajectories between the different cells of the 3 clusters we 286 
calculated diffusion maps and diffusion pseudotime. This analysis revealed a developmental 287 
trajectory originating from the HB cluster, which bifurcated towards either the Hep cluster or 288 
Chol cluster (Fig. 5C). We found the HB cluster contained a higher proportion of cells in G2M 289 
phase, indicating an increased number of proliferative cells (Figs. 5C,S5B). When analysing 290 
the lineage trajectories we took advantage of the Lgr5-EGFP-IRES-creERT2 mouse line 291 
(Barker et al., 2007), which enabled us to identify cells that expressed Lgr5 RNA via 292 
sequencing and determine whether they were GFP+ during FACS (Fig. 5D,E). Since the GFP 293 
protein is more stable than the transcript, we used the comparison between the Lgr5-GFP+ 294 
sorted cells and the cells expressing Lgr5 transcript as a proxy to identify the immediate 295 
descendants of Lgr5+ cells in the scRNA-seq population. Notably, most of the Lgr5+ cells 296 
mapped to the HB cluster, representing 2% of the total number of Liv2+ hepatoblasts at E10.5 297 
(Fig. S5C). Interestingly, we observed that, as cells exit the HB cluster and become committed 298 
to either of the two epithelial lineages, Lgr5 transcript levels decrease (Fig. 5D, black arrows). 299 
Many of these transitioning cells (Fig. 5E, black arrows) were negative for Lgr5 transcript but 300 
positive for GFP, indicating that these cells have only recently reduced Lgr5 levels as the GFP 301 
protein has not yet degraded and so can be considered immediate descendants of the Lgr5+ 302 
pool. Finally, once cells have transitioned to the Hep cluster, Lgr5 is upregulated, whilst Lgr5 303 
expression is not reinitiated in the Chol cluster. 304 
 305 
Segregation of the data by embryonic stage shows that E10.5 cells contribute to the HB cluster, 306 
the intermediate cells that are moving from the HB cluster towards the Hep cluster, the Hep 307 
cluster and cells located at the far end of the Chol cluster (Fig. 5F). At E10.5, though, we find 308 
very few cells in the transition between the HB and Chol clusters. However, some of them were 309 
Lgr5GFP+ that had downregulated Lgr5 transcript, suggesting that they were immediate 310 
descendants of the E10.5 Lgr5+ HB cluster cells. Cells occupying this intermediate space were 311 
readily identified at E13.5, the majority of which also appear to have recently downregulated 312 
Lgr5, again indicating that they were immediate descendants of the Lgr5+ cells of the HB 313 
cluster. This implies that the proliferating Lgr5+ hepatoblasts do indeed give rise to 314 
cholangiocytes at E10.5, but with a higher proportion at E13.5. Intriguingly, E13.5 cells (both 315 
Lgr5GFP+ and bulk) contributed significantly to the Chol cluster, but we did not find E13.5 316 
cells that mapped to the Hep cluster (Figs. 5F,S5D). This result was in striking disagreement 317 
with our knowledge of liver development and our E13.5 lineage tracing results from the Lgr5-318 
IRES-CreERT2 allele, which provided evidence that E13.5 Lgr5+ tracing results in labelling 319 
of only hepatocytes (Fig. S1B) indicating that, at E13.5, cells committed to a hepatocyte fate 320 
are indeed present and express Lgr5. Our interpretation of this discrepancy between the lineage 321 
tracing and the scRNA-seq data is that the cells along the hepatocyte trajectory from E13.5 no 322 
longer express the epitope for the anti-Liv2 antibody used during FACS, and thus were not 323 
subject to sequencing.  324 
 325 
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Together, our scRNA-seq analysis suggested that the E10.5 embryonic liver harbours distinct 326 
sub-populations of liver progenitors that co-exist within the hepatoblast pool; a Lgr5+ sub-327 
population that contributes to both hepatocyte and cholangiocytes and a previously 328 
unrecognized sub-population of already cholangiocyte committed cells that has already 329 
downregulated Lgr5 and started its specification to cholangiocyte fate. 330 
 331 
Lgr5 marks the apex cells within a E9.5 heterogeneous hepatoblast pool 332 
 333 
Our lineage tracing and single-cell RNA sequencing data showed that Lgr5 labels bipotent 334 
hepatoblasts that differentiate towards hepatocyte or cholangiocyte fates. This is indicative of 335 
a hepatoblast hierarchy, and suggested Lgr5 as a potential marker of cells at its apex. 336 
Quantifying the number of tracing events as well as their contribution to the postnatal tissue 337 
provides information on the potency and commitment of a given population in the developing 338 
tissue. To determine whether Lgr5+ cells reside at the apex of a developmental hierarchy, we 339 
reasoned that the cell composition of their clonal progeny must reflect quantitatively the 340 
corresponding proportions in tissue. Therefore, we quantified the proportion of labelled 341 
hepatocytes and cholangiocytes following lineage tracing from Lgr5-IRES-CreERT2 at E9.5 342 
(Fig. 6A) and compared the proportions to the representative homeostatic distributions (Fig. 343 
6B). We found that the homeostatic proportion of hepatocytes and cholangiocytes in the mouse 344 
postnatal liver is 96.6 ± 0.6% and 3.4 ± 0.6%, respectively, (Fig. S6A,B,C and Supplementary 345 
dataset 3_S4); consistent with previous reports in rats (Blouin et al., 1977). Remarkably, we 346 
found that lineage tracing with Lgr5-IRES-CreERT2 at E9.5 resulted in labelled cells in which 347 
96.7 ± 0.5% were hepatocytes and 3.3 ± 0.5% were cholangiocytes, the same proportions as 348 
the homeostatic liver (Fig. 6C). Therefore, although we cannot rule out altogether the potential 349 
parallel contribution of a Lgr5- cell lineage that produces differentiated progeny in proportions 350 
representative of tissue, these results suggest strongly that Lgr5 expression marks hepatoblasts 351 
that constitute the apex of the differentiation hierarchy. 352 
 353 
When analysing our single-cell RNA sequencing data, we found that, at E10.5, there were 354 
cholangiocyte-like cells that did not express Lgr5, suggesting that there were cholangiocyte-355 
committed hepatoblasts even at this very early time-point. To formally investigate whether this 356 
was a genuine functional heterogeneity or was only reflecting transcriptional heterogeneity at 357 
this time-point, we turned to a second lineage tracing strategy using a ubiquitous and unbiased 358 
driver: the R26R-CreERT2. Lineage tracing from R26R-CreERT2 will label all cell types in the 359 
developing liver, including Lgr5+ and Lgr5- hepatoblasts. No labelling was detected in non-360 
induced mice (Fig. S2D), therefore, labelled hepatocytes and cholangiocytes in postnatal livers 361 
will represent descendants of any hepatoblasts labelled at E9.5 (Fig. 6D). Strikingly, when 362 
labelled with the unbiased R26R-CreERT2 allele at E9.5, we found a significantly higher 363 
proportion of labelled cholangiocytes compared to the homeostatic proportion (R26R-CreERT, 364 
7.7 ± 1.9% cholangiocytes vs 3.3 ± 0.5% with Lgr5-IRES-CreERT2) (Fig. 6C). These results 365 
were confirmed using two independent multicolour R26R-reporter alleles (R26R-Confetti and 366 
R26R-Rainbow). These findings are in agreement with our scRNA-seq data, in which we had 367 
observed that E10.5 hepatoblasts were already committed to a cholangiocyte fate.  368 
 369 
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In contrast to induction at E9.5, Cre induction from the R26R-CreERT2 allele at E13.5 gave 370 
rise to labelled hepatocytes and cholangiocytes in homeostatic proportions (Fig. 6C), whilst 371 
lineage tracing from the Lgr5-IRES-CreERT2 allele at E13.5 gave rise solely to labelled 372 
hepatocytes (Fig. 6C), suggesting that Lgr5+ cells lose their bipotency and position in the 373 
hierarchy during the developmental progression. These results indicate that hepatoblasts are 374 
not only heterogeneous in progenitor potential but their competence to generate hepatocytes 375 
and cholangiocytes changes between E9.5 and E13.5. 376 
 377 
In addition to the identity of labelled cells, the size of labelled clusters generated from the Lgr5-378 
IRES-CreERT2 and R26R-CreERT2 alleles was quantified as a proxy for the proliferative 379 
potential of the initially labelled hepatoblast. We found that tracing with the Lgr5-IRES-380 
CreERT2 allele at E9.5 gave rise to larger clusters of labelled cells than tracing with the R26R-381 
CreERT2 allele (Fig. 6E,F). The larger cluster sizes from Lgr5+ hepatoblasts indicate that these 382 
cells have a greater proliferative potential than, and developmental advantage over, the bulk 383 
hepatoblast population, again suggestive of their position at the apex of the hepatoblast 384 
hierarchy. 385 
 386 
Our combined findings lead us to conclude that the E9.5 hepatoblast population is indeed 387 
functionally heterogeneous, with Lgr5+ hepatoblasts residing at the apex of the E9.5 hierarchy 388 
and a population of non-Lgr5+ hepatoblasts exhibiting a previous unidentified early 389 
commitment to the cholangiocyte fate.  390 
 391 




The Wnt target gene Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5) has 395 
been described as a marker of stem cells in non-damaged, self-renewing, tissues such as the 396 
intestine, stomach and hair follicles, as reviewed in (Barker et al., 2010). In the adult liver, 397 
Lgr5 is lowly-expressed during homeostasis. However, upon damage, Lgr5 becomes highly 398 
upregulated in a subset of cells, which contribute to the regeneration of both hepatocytes and 399 
cholangiocytes. Similarly, Lgr5 is also upregulated in homeostatic liver ductal cells, when 400 
cultured as self-renewing bipotential liver organoids (Huch et al., 2013). Here we found that 401 
Lgr5 marks a previously unknown bipotent Lgr5+ population, which resides at the apex of an 402 
E9.5 heterogeneous hepatoblast pool. 403 
To date, bipotentiality of hepatoblasts has only been shown at the population level (Yanagida 404 
et al., 2016). However, at least in vivo, there has been no experimental proof regarding 405 
bipotentiality of individual hepatoblast cells. A recent report showed that a labelled Foxa2+ 406 
definitive endoderm cell induced at E7.75 gives rise to cells moving towards hepatocyte and 407 
cholangiocyte fates at E16.5, suggesting that, at least before hepatic specification at E7.75, the 408 
definitive endoderm progenitors are multipotent (El Sebae et al., 2018). Similarly, in vitro, 409 
Dlk+ embryonic liver cells at E14.5 were found to express markers of both hepatocyte and 410 
cholangiocyte lineages (Tanimizu et al., 2003), again suggestive of the bipotent nature of 411 
hepatoblast cells. However, formal proof of bipotential hepatoblasts in vivo has not yet been 412 
provided. Here, using lineage tracing with a multicolour reporter we unequivocally 413 
demonstrate that E9.5 Lgr5+ hepatoblasts are indeed bipotent in vivo, as single clones 414 
consisting of cholangiocytes and hepatocytes are present at the portal triad (Fig. 3C,D). 415 
Whether Lgr5+ E9.5 hepatoblasts directly give rise to hepatocytes and cholangiocytes, or 416 
whether a fraction pass through a ductal-like precursor state as suggested in a recent study 417 
(Carpentier et al., 2011), remains an interesting and open question. 418 
Alongside bipotent clones, we also found clones formed of hepatocytes without cholangiocytes 419 
throughout the liver; including in the portal region (zone 1). This can have two possible 420 
explanations: either a subset of Lgr5+ cells is unipotent for hepatocyte fate and others are 421 
bipotent or, alternatively, all the Lgr5+ cells harbour, but may not exploit, multilineage 422 
potential. The first option (only a subset is bipotent) implies that there is engrained 423 
heterogeneity within the Lgr5+ population regarding their potentiality. In that regard, our 424 
single-cell RNA-seq data, where we find Lgr5+ cells in both the hepatoblast and the hepatocyte 425 
clusters, suggest that this could indeed be a plausible scenario. Alternatively, one could 426 
hypothesise that all the Lgr5+ cells are bipotent but depending on external signals received 427 
according to the specific position of the original Lgr5+ progenitor cell, they may differentiate 428 
into one or two cell types. This implies that developmental stage and local environment could 429 
be critical in defining the final fate of a given Lgr5+ hepatoblast. In that regard, the fact that 430 
embryonic Lgr5+ cells isolated by FACS and cultured in vitro were sensitive to the growth 431 
factors present in the culture medium, and committed either to the cholangiocyte or hepatocyte 432 
lineage according to media composition, would argue in support of this latter argument (Fig. 433 
4). It is tempting to speculate that by retaining Lgr5+ cells at defined positions during liver 434 
 13 
growth by maintenance of a specific local environment, differentiation into cholangiocytes 435 
would occur as daughter cells exited such a niche. This is consistent with current evidence of 436 
the discontinuous growth of the liver ductal network as reviewed in (Ober and Lemaigre, 2018), 437 
although there is at present no direct evidence for a role of Lgr5+ cells in directing liver 438 
morphogenesis.  439 
Interestingly, lineage tracing at E13.5 from the Lgr5-IRES-CreERT2 allele resulted in labelling 440 
of only hepatocytes (Fig. 6C,S1B), whilst E13.5 lineage tracing from the R26R-CreERT2 allele 441 
resulted in labelling of both hepatocytes and ductal cells in the homeostatic proportions (96.4% 442 
and 3.6%, respectively). These results underline the continual shift in cell potency and cell 443 
surface marker expression throughout development of the liver and are consistent with other 444 
reports in which a single cell surface marker is not adequate to define a particular cell type 445 
(hepatoblast, hepatocyte or cholangiocyte) throughout the entirety of liver development 446 
(Tanaka et al., 2009). Instead, a set of two or more cell surface markers will have to be used to 447 
define each cell type at specific stages of development. In that regard we found that, while Liv2 448 
is indeed a good marker of the hepatoblast pool at E10.5, it is not appropriate to identify 449 
unbiased hepatoblasts at E13.5, as it seems to mark hepatoblasts already biased towards the 450 
ductal fate.  451 
 452 
In contrast to the widely accepted view that differentiation of hepatoblasts into cholangiocytes 453 
occurs from E13.5 onwards (Gordillo et al., 2015), our results provide the functional 454 
demonstration that heterogeneity already exists at E9.5. Our scRNA-seq data shows that, even 455 
as early as E10.5, there is heterogeneity within the hepatoblast population, with some cells 456 
already moving towards cholangiocyte or hepatocyte fates. We identify sub-populations of 457 
hepatoblasts that express Lgr5 whilst other sub-populations do not. Further, some of these 458 
Lgr5- cells already express markers of cholangiocyte fate. Consistent with the scRNA-seq data, 459 
our functional studies that fate map E9.5 liver progenitors using lineage tracing from either 460 
Lgr5-IRES-CreERT2 or R26R-CreERT2 demonstrate the existence of both Lgr5+ and Lgr5- 461 
hepatoblasts already at E9.5 (Fig. 6C). Importantly, induction of lineage tracing at E9.5 using 462 
Lgr5-IRES-CreERT2, but not R26R-CreERT2, resulted in labelled postnatal hepatocytes and 463 
cholangiocytes in homeostatic proportions (97% hepatocytes vs 3% cholangiocytes), implying 464 
that Lgr5+ cells behave functionally as a genuine bipotent hepatoblast and are indeed at the 465 
apex of its hepatoblast hierarchy. On the contrary, unbiased labelling using the R26R-CreERT2 466 
model, gave rise to a higher proportion of cholangiocytes at E9.5, compared to the homeostatic 467 
or Lgr5+ descendants, arguing in favour of an already cholangiocyte-committed hepatoblast 468 
sub-population, negative for Lgr5, in the E9.5 developing liver. This result suggests that E9.5 469 
Lgr5+ cells are at the apex of their hierarchy, i.e. are bipotent and equipotent, and are able to 470 
give rise to already lineage-restricted ductal progenitors that downregulate Lgr5 and expand in 471 
order to contribute to the postnatal ductal pool. While our results demonstrate that Lgr5 472 
expression overlaps with the apex of a hepatoblast pool, they do not show functionally that 473 
Lgr5 expression defines the apex of the hepatoblast pool. Lgr5 expression could be subjected 474 
to local environmental factors and just mark a subpopulation of cells that receives high Wnt 475 
signalling. Then, one could speculate that Lgr5 negative hepatoblasts with the very same 476 
potency as the Lgr5+ ones also reside at the apex of their own hierarchies. This implies that 477 
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populations of equally potent hepatoblasts, some of which express Lgr5 and are bipotent, co-478 
exist at this time-point in development. If these additional hepatoblasts populations indeed 479 
exist, the nature of their identity and bipotentiality are still questions that remain to be 480 
addressed.   481 
 482 
In summary, using a combination of lineage tracing, organoid cultures and scRNA-seq analysis 483 
we show that the E9.5 hepatoblast pool is heterogeneous, not only at the RNA, but also at the 484 
functional level. Within the different E9.5 hepatoblast sub-populations, we find that Lgr5 485 
marks a previously unknown bipotent Lgr5+ population, which resides at the apex of its E9.5 486 
hepatoblast hierarchy. Furthermore, we also describe a previously unidentified sub-population 487 
of cholangiocyte-committed cells that do not express Lgr5. To our knowledge, this is the first 488 
report that recognizes the functional heterogeneity of the E9.5 hepatoblast pool and the first 489 
demonstration that Lgr5 is a bona fide marker of early bipotent hepatoblasts in the developing 490 
liver. Our studies raise further questions about the nature of Lgr5 in liver development and 491 
liver morphogenesis. Wnt signalling has been implicated in liver growth (McLin et al., 2007; 492 
Micsenyi et al., 2004; Tan et al., 2008). However, its role in determining the potency of 493 
hepatoblasts is unknown. Elucidating the functional role, if any, for Lgr5 in liver development 494 
could help to clarify the part played by Wnt signalling. However, knock-down experiments 495 
may not be sufficient to address the role of Lgr5 due to the presence of other homologues, like 496 
Lgr4, which is expressed during liver development (Camp et al., 2017), and could compensate 497 
for the loss of function of Lgr5, as is reported for the adult intestine (de Lau et al., 2011). 498 
Therefore, it remains unclear whether Lgr5 per se has a functional role in liver development. 499 
Similarly, cell ablation studies would be required to address whether the Lgr5+ hepatoblast 500 
rather than the Lgr5 gene per se, is indeed required during development. Due to the widespread 501 
expression of Lgr5+ stem cells in the adult and in other embryonic tissues, it is not trivial to 502 
assess the functionality of Lgr5+ cells in a specific tissue. We have shown that isolated Lgr5+ 503 
hepatoblasts can be cultured in vitro, and so this may provide a reductionist system in which 504 
we can test the requirement for Lgr5 in establishing or maintaining bipotency in hepatoblasts 505 
without the confounding effects of signalling from other tissues. Finally, it would be of interest 506 
to investigate whether the adult ductal-regenerative response, in which Lgr5 is upregulated in 507 
regenerative liver cells recapitulates the same programmes from embryonic development. 508 
Future studies would aim at addressing these questions.   509 
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Materials and Methods 510 
Mouse strains and animal work 511 
Lgr5-IRES-CreERT2 (Huch et al., 2013), Lgr5-EGFP-IRES-creERT2 (Barker et al., 2007), 512 
R26R-TdTomato (Madisen et al., 2010), R26R-Confetti (Snippert et al., 2010), R26R-513 
CreERT2 (Ventura et al., 2007) and R26R-Rainbow1.0 (Livet et al., 2007) mice were described 514 
previously. All mouse experiments have been regulated under the Animals (Scientific 515 
Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the 516 
University of Cambridge Animal Welfare and Ethical Review Body (AWERB) and have been 517 
performed in accordance with the Home Office license awarded to M.H.   518 
Tamoxifen induction 519 
Lineage tracing was performed using the R26R-TdTomato or R26R-Confetti or R26R-520 
Rainbow1.0 reporter in combination with a temporally inducible Cre, either Lgr5-IRES-521 
CreERT2 or R26R-CreERT2. To induce Cre activity tamoxifen (Sigma, T5648) was 522 
administered by intraperitoneal injection of the pregnant female at the specified embryonic 523 
day. Tamoxifen doses were dependent on the reporter line and Cre line used. For details refer 524 
to Supplementary dataset 2_S1_S2. Embryos and pups (male and females) were then collected 525 
at specified time-points according to the experiment.  526 
Tissue preparation and immunostaining   527 
Embryonic and postnatal livers were dissected and fixed for 2 h or 24 h, respectively in 10% 528 
neutral- buffered formalin (Sigma-Aldrich) at 4oC. Postnatal livers were embedded in 4% low 529 
melting point agarose (BioRad Laboratories) and sectioned at 100μm using a Leica VT1000S 530 
microtome. E10.5 and E11.5 samples were equilibrated with 30% sucrose and embedded in 531 
OCT compound	(VWR,	361603E)	and	frozen	on	dry	ice in preparation for sectioning with a 532 
Leica	 CM-3050S	 cryostat at 50µm. To reduce nonspecific staining and permeabilize the 533 
sample, samples were incubated with a 2% donkey serum, 1% Triton, 5% DMSO in PBS 534 
solution overnight at 4°C. Primary antibodies were then applied at appropriate dilutions for 48 535 
h at 4°C, for details refer to Supplementary dataset 3_S1. Samples were washed and secondary 536 
antibodies applied at dilution 1:250 for 48 h at 4oC. Nuclei were counterstained with Hoechst 537 
33342 (1:1000, Invitrogen) for 30 min at room temperature. 538 
 539 
Confocal Imaging 540 
Samples were imaged on a SP8 White Light inverted confocal microscope (Leica 541 
Microsystems) through a 10x or 20x objective using a Leica application suite X Software. 542 
Optical sections were acquired at 2µm intervals. Images were processed using Fiji. 543 
 544 
Frequency of merger events 545 
To calculate the frequency of mergers of the same colour we followed the calculations 546 
published in (Aragona et al., 2017). Briefly, the probability of unicolour mergers is 547 
proportional to the frequency of bicolour mergers involving a given colour taking into account 548 
different induction frequencies between colours. This analysis was conducted using the livers 549 
in which bipotent clones were quantified. 550 
 16 
Automated Cell Counting of homeostatic proportions 551 
Automated cell counting was conducted on immunofluorescent images (stained for osteopontin 552 
and Hoechst) of P0, P14 and P30 liver sections to determine the homeostatic proportions of 553 
hepatocytes and cholangiocytes in the postnatal liver. First, images were segmented using 554 
ilastik-1.2.2 software. In this way, immunofluorescent images consisting of a Hoechst channel 555 
and an Osteopontin channel were used to train the machine learning software to segment 556 
cholangiocytes (primarily based on co-expression of osteopontin), hepatocytes (primarily 557 
based on their characteristic large round nuclei), other cells (primarily based on a lack of 558 
osteopontin co-staining and smaller, brighter nuclei) or background (based on a lack of signal). 559 
The segmented images were then imported into Fiji and using the Threshold plugin the specific 560 
hepatocyte or cholangiocyte segments were selected. A selection was created around the 561 
hepatocyte or cholangiocyte segments and overlaid on the Hoechst channel, which clearly 562 
shows individual cells. Within the cholangiocyte or hepatocyte selections, the number of cells 563 
were counted using the find maxima function on the Hoechst channel. 564 
 565 
AFP and Albumin secretion assays 566 
To assess AFP and albumin secretion the Mouse alpha Fetoprotein ELISA Kit (Abcam) and 567 
the Mouse Albumin ELISA kit (AssayPro), respectively were used according to the 568 
manufacturers’ instructions (Supplementary dataset 3_S2). Supernatants were collected 24 hr 569 
following the latest medium change, 570 
Isolation of cells for single cell RNA sequencing and in vitro culture 571 
Lgr5GFP
het and Lgr5GFP
-/- embryos were collected at the specified time-points and screened 572 
for GFP signal with an epi-florescence microscope. Once classified according to phenotype, 573 
livers were collected and minced before enzymatic digestion. Enzymatic digestion was 574 
performed at 37oC with Wash medium (constituting DMEM+ GlutaMAX (Invitrogen) 575 
supplemented with 1% FBS and 1x penicillin/streptomycin) containing 0.125 mg/ml 576 
Collagenase Type I (Sigma-Aldrich) and Dispase II (Gibco) and 0.1 mg/ml DNase (Sigma 577 
Aldrich). The incubation time for enzymatic digestion was approximately 40 min for E10.5 578 
livers and 2 h for E13.5 livers. Once the digestion to single cells was confirmed by visual 579 
inspection, samples were filtered through a 40 μm pore size nylon cell strainer (Falcon) and 580 
centrifuged at 400 g for 5mins. The pellet was resuspended in blocking solution (Wash medium 581 
with 2% FBS, Rho kinase inhibitor Y27632 (Sigma Aldrich) and 0.1 mg/ml DNase) for 20 582 
min. Cells were then centrifuged at 400 g for 5 min and incubated with primary antibody 583 
against Liv2 (1:100, MBL) in Wash medium supplemented with rock inhibitor and DNase for 584 
40 min on ice. Cells were then pelleted at 400 g for 5 min and washed. Cells were incubated 585 
with APC anti-rat (Biolegend) for anti-Liv2, CD31-PE/Cy7 (abcam) and CD45-PE/Cy7 586 
(Bioscience) diluted in Wash medium supplemented with rock inhibitor and DNase for 40 min 587 
on ice. The sorting strategy consisted of a population of single cells that were sequentially 588 
gated based on cell size (forward scatter, FSC, versus side scatter, SSC), singlets (pulse width 589 
vs FSC) and Liv2-APC positivity. Finally, CD45-PE/Cy7 (BD Biosciences), CD31-PE/Cy7 590 
(Abcam) antibodies were used in order to exclude blood cells and endothelium. Liv2+/CD31-591 
/CD45- (bulk hepatoblast pool) or Liv2+/CD31-/CD45-/GFP+ cells (named as Lgr5+ cells) were 592 
used for further analysis.  593 
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 594 
For single cell RNA sequencing experiments cells were sorted on an influx Cell Sorter (BD 595 
Biosciences). Single cells were collected in non-skirted PCR plates containing lysis buffer 596 
(0.2% triton (Sigma triton X-100 solution) in 1 U per µl RNase inhibitor (Thermo Fisher 597 
Scientific) in DEPC-water (Ambion)). Plates were then vortexed and centrifuged at 2000 rpm 598 
for 2 mins and kept at -80°C. For 3D in vitro culture cells were sorted on a MoFlo into Sort 599 
medium (Advanced DMEM/F12 (GIBCO) supplemented with 1% penicillin/streptomycin, 1% 600 
Glutamax, 10 mM HEPES, 1x B27 supplement (without vitamin A), 1.25 mM N-acetyl-l-601 
cysteine, 10% (vol/vol) Rspo-1 conditioned medium, 10 mM Nicotinamide, 10 nM 602 
recombinant human (Leu15)-gastrin I, 50 ng/ml recombinant mouse EGF, 100 ng/ml 603 
recombinant human FGF10, 25 ng/ml recombinant human HGF, 1 nM A8301, and 10 µM 604 
Y27632. 605 
 606 
Single cell RNA sequencing 607 
scRNA-seq sample preparation was performed with an adapted version of Smartseq2 (Picelli 608 
et al., 2014). cDNA was reverse transcribed using 50 U. reaction SmartScribe Reverse 609 
Transcriptase (Takara ClonTech) without Betaine and MgCl2 and amplified using KAPA HiFi 610 
Hotstart polymerase (Roche). Illumina Nextera XT DNA preparation kit was used to prepare 611 
libraries and pooled libraries were sequenced using the Illumina HiSeq 4000 system (single-612 
end 50 bp reads). The quality of the reads was examined with FastQC 613 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The reads were aligned to 614 
genome version GRCm38, with the 92 Spike-in transcript sequences added, using STAR 615 
(v2.6.0c) and Ensemble gene annotation version 93 (Kersey et al., 2018). subread (v1.6.2) was 616 
used to count uniquely aligned reads using the same Ensemble annotation and to create the 617 
count matrix. Further analysis was performed using scanpy (v1.3.3) (Wolf et al., 2018b). For 618 
quality control of cells, the following quality metrics were calculated for each cell: (1) the 619 
percentage mitochondrial transcript reads, (2) the percentage of Spike-In reads, (3) the total 620 
number of reads, and (4) the log10 transformed number of genes with at least one read. Only 621 
cells with (1) less than 20% of mitochondrial reads, (2) less than 25% Spike-In reads and (3) 622 
more than 100.000 reads were considered for downstream analysis. As the log10 transformed 623 
number of genes with at least one read (4) showed clear batch effects, the four different 624 
thresholds 3.6, 3.5, 3.7, and 3.5 were applied to the four different sorts and only cells exceeding 625 
these thresholds passed quality control. In total, 653 (69%) of 943 cells were considered for 626 
downstream analysis. Because an initial principal component analysis revealed batch effects 627 
between the biological replicates from experiments 1, 2 and 4 (group 1) on the one hand and 628 
experiment 3 (group 2) on the other hand, batch correction between those two groups was 629 
performed: For each group, only genes expressed in at least 3 cells were considered. The counts 630 
in each group were normalised using size factors computed with the scran (v1.8.4) function 631 
computeSumFactors (parameters: min_mean=1.0, size=seq(20, 100, 5)) (Lun et al., 2016). For 632 
each group, highly variable genes were detected using the scanpy function 633 
filter_genes_dispersion (parameter: max_mean=8) and the intersection of both gene sets, 634 
which contained 1766 genes, was used for further analysis. Batch effects between the two 635 
datasets were corrected by matching mutual nearest neighbours in the implementation of 636 
mnnpy (v0.1.9.3) (parameters: svd_mode=’irlb’) (Lun et al., 2016). On the resulting count 637 
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matrix, a principal component analysis was performed. t-SNE dimensionality reduction was 638 
performed on the first 20 principal components using  the MulticoreTSNE implementation 639 
(paramters: perplexity=80, early_exageration=12) (Amir et al., 2013). To perform Louvain 640 
clustering, the 15-nearest neighbours graph was computed on the first 20 principal components. 641 
Using Louvain clustering with the resolution parameter set to 0.05, 3 clusters were obtained 642 
(Levine et al., 2015; Subelj and Bajec, 2011). Differentially expressed genes were detected by 643 
performing a Wilcoxon rank-sum test on the raw counts comparing each cluster against the 644 
union of the other two clusters as implemented in scanpy’s rank_genes_groups function. To 645 
define marker genes for the clusters at specific embryonic stages, the cells were grouped 646 
according to cluster and stage and a Wilcoxon rank-sum test was performed as described above. 647 
For the sub-clustering of the cholangiocyte-like cluster, a principal component analysis was 648 
performed on those cells and then clustering was performed as above with the resolution 649 
parameter set to 0.5. Differentially expressed genes between the two resulting sub-clusters were 650 
detected as described above. The diffusion maps were calculated using the scanpy function 651 
diffmap with the width of the Gaussian connectivity kernel being implicitly determined by the 652 
distance to the 100 nearest neighbours in the space of the 20 first principal components 653 
(Coifman et al., 2005; Haghverdi et al., 2015). Diffusion pseudotime was calculated using 654 
scanpy’s dpt function using the cell with minimal diffusion component 1 as root cell 655 
(Haghverdi et al., 2016; Wolf et al., 2018a).Cell cycle phases were assigned using cyclone and 656 
the pre-trained mouse cycle markers contained in the scran package (Scialdone et al., 2015). 657 
Cells were classified as Lgr5 positive on the transcript level if they had more than 10 reads of 658 
Lgr5. The code is available on GitHub at https://github.com/fabianrost84/prior_et_al_2019. 659 
 660 
3D culture of embryonic liver cells  661 
Following isolation as described in isolation section above, the cells were pelleted at 400 g and 662 
seeded in Matrigel (BD Biosciences) and cultured either with the hepatocyte-like protocol or 663 
cholangiocyte-like protocol. The hepatocyte-like method involves culturing for the first 3 days 664 
in Advanced DMEM F12 supplemented with Penicillin/Streptomycin, Glutamax and HEPES 665 
(Gibco), 1xB27 (Gibco), 500 nM n-Acetylcysteine (Sigma), 10 mM Nicotinamide (Sigma), 666 
100 ng/ml FGF10 (Peprotech), 100 ng/ml FGF7 (Peprotech), 50 ng/ml HGF (Peprotech), 10 667 
nM Gastrin (Sigma), 50 ng/ml EGF (Peprotech), 1 nM A83-01 (Tocris Bioscience), 3µM CHIR 668 
99021 (Tocris Bioscience), 15% R-spondin 1 conditioned medium (in house), and 10 µM Rock 669 
inhibitor Y-27632 (Sigma). From day 3 onwards the culture medium was modified by the 670 
exclusion of FGF7. The cholangiocyte-like method consists of culturing for the first 3 days in 671 
Advanced DMEM F12 supplemented with Penicillin/Streptomycin, Glutamax and HEPES 672 
1xB27, 500 nM n-Acetylcysteine, 10 mM Nicotinamide, 100 ng/ml FGF10, 50 ng/ml HGF, 10 673 
nM Gastrin, 25 ng/ml Noggin (Peprotech), 50 ng/ml EGF, 1 nM A83-01, 10µM Forskolin 674 
(Tocris Bioscience), 10% R-spondin 1 conditioned medium, 30% Wnt conditioned medium (in 675 
house) and 10 µM Rock inhibitor Y-27632 (Sigma). From day 3 onwards the culture medium 676 
was modified by the exclusion of the Wnt conditioned medium and removal of Noggin. After 677 
several days in culture, organoid structures with either a cystic (cholangiocyte-like medium) or 678 
solid (hepatocyte-like medium) form arose. Cultures were split at 1:2 ratio after 14-20 days. 679 
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Figure legends 895 
 896 
Figure 1: Lgr5 expression marks cells with hepatoblast features in the developing liver. 897 
(A-C) Lgr5-IRES-CreERT2hom; R26R-TdTomatohom males were bred with MF1-WT females in 898 
order to generate Lgr5-IRES-CreERT2het;R26R-TdTomatohet embryos. Administration of 899 
tamoxifen to pregnant females at E9.5 leads to activation of Cre in Lgr5+ cells and 900 
recombination at the ROSA locus to induce expression of TdTomato in E9.5-E10 Lgr5+ cells 901 
and their progeny. (A) Schematic of experimental approach. Expression of TdTomato can be 902 
detected in E11.5 livers following induction at E9.5, indicating the presence of Lgr5+ cells in 903 
the developing liver at E9.5 (n≥3 independent experiments, n=2 independent litters). 904 
Representative image of TdTomato epi-fluorescence (red) is shown. Nuclei were 905 
counterstained with Hoechst (grey). (B) Representative immunofluorescent staining of 906 
TdTomato-expressing cells co-stained with the hepatoblast marker AFP (green, top panel), 907 
endothelial marker VEGFR3 (green, middle top panel), pan-haematopoietic marker CD45 908 
(green, middle bottom panel) and the proliferative marker Ki67 (green, bottom panel). (C) 909 
Quantification of the immunostainings shown in B. 100% of TdTomato+ cells co-express AFP 910 
and are negative for endothelial and haematopoietic fate markers (n>30, n=2 independent 911 
litters). At least half of TdTomato+ cells are proliferative (Ki67+, n>50, n=2 independent 912 
litters). 913 
 914 
Figure 2: Lgr5 is a marker of bona fide hepatoblasts in vivo. 915 
(A) Schematic of experimental approach. TdTomato expression was induced at E9.5 and livers 916 
collected at the indicated postnatal time-points. (B) Lgr5+ progeny (TdTomato+ cells, red) are 917 
found distributed along all 3 zones of the liver lobule; the portal triad (PT, zone 1), the central 918 
vein (CV, zone 3) and the intermediate region (zone 2) at all time-points analysed, up to 12 919 
months after birth. In the portal area labelled cells include both hepatocytes and cholangiocytes 920 
(Osteopontin, green), indicating that E9.5-E10 Lgr5+ cells are bona fide hepatoblasts. Right 921 
panels represent a magnified area from zone 1. 922 
 923 
Figure 3: E9.5 Lgr5+ hepatoblasts are bipotent. 924 
(A-D) Lgr5-IRES-CreERT2hom mice were mated with multicolour Confetti reporter R26R-925 
Confettihom mice to generate Lgr5-IRES-CreERT2het;R26R-Confettihet embryos. Induction with 926 
tamoxifen at E9.5 results in Lgr5+ cells and progeny being labelled in one of four colours 927 
(RFP, YFP, mCFP, nGFP). (A) Schematic of experimental design. Two potential outcomes are 928 
illustrated; a single Lgr5+ hepatoblast (red circle) is bipotent and gives rise to both hepatocytes 929 
(red squares) and cholangiocytes (red triangles) or, alternatively, single Lgr5+ hepatoblasts 930 
(blue and yellow circles) are unipotent and independently give rise to hepatocytes (blue 931 
squares) and cholangiocytes (yellow triangles). (B-C) Representative images of P0 Lgr5-IRES-932 
CreERT2het;R26R-Confettihet  liver following induction at E9.5. Ductal cells were co-stained 933 
with Osteopontin (blue, white arrows). Nuclei were stained with Hoechst. (B) Low power 934 
magnification of a liver section showing a red and a yellow clone (white arrows). (C) 935 
Magnification showing that the red clone contains both hepatocytes and cholangiocytes (white 936 
arrows).  (D) Pie charts showing the total number of clones identified (n=70) and the fraction 937 
of these that are located in the portal area (n=26). Note that from the total number of clones 938 
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found in the portal area, half of them (n=13) contained both hepatocytes and cholangiocytes of 939 
the same colour. At the induction dose used, the frequency of mergers of clusters of the same 940 
colour is less than 3.6 ± 1.9% for all colours, (see Supplementary Fig. 2B), which confirms that 941 
at least 12 of the 13 bipotent clones identified arise from a single Lgr5+ cell, demonstrating 942 
that a fraction of Lgr5+ cells are bipotent at E9.5. Experiments were performed in n=3 embryos.   943 
 944 
Figure 4: Lgr5+ embryonic liver cells form both cholangiocyte-like and hepatocyte-like 945 
organoids in vitro. 946 
(A) Section of an E10.5 liver showing co-labelling of Lgr5-GFP+ cells (green) with the liver 947 
progenitor marker Liv2 (purple). Nuclei were counterstained with Hoechst. (B-H) Embryonic 948 
liver organoids were generated from sorted Lgr5-GFP+ hepatoblasts isolated from E10.5-949 
E12.5 Lgr5-EGFP-IRES-creERT2 livers. (B) Schematic of the experimental approach. (C-D) 950 
Representative image of a mouse embryo liver organoid derived from a single Lgr5-GFP+ cell 951 
and cultured in (C) cholangiocyte-like medium or (D) hepatocyte-like medium (Day 0 & 2 952 
scale bar =10µm). Note the hepatocyte morphology of cells in the organoids grown in 953 
hepatocyte-like medium. (E) Expression of the ductal marker Krt19 is predominantly detected 954 
in embryonic organoids grown in cholangiocyte-like medium and in control adult ductal liver 955 
organoids, while the hepatocyte marker Albumin (Alb) is detected at much higher levels in 956 
embryonic cells cultured in hepatocyte-like medium. (F) Immunofluorescence staining of 957 
organoids derived from Lgr5-GFP+ embryonic liver cells shows clear expression of either the 958 
ductal marker Krt19 in organoids grown in cholangiocyte-like medium (left panel) or the 959 
hepatocyte marker HNF4α in organoids grown in hepatocyte-like medium (right panel), (nuclei 960 
counterstained with Hoechst, membranes labelled with Ctnnb1). The image of embryonic 961 
organoids grown in cholangiocyte-like medium represents a projection of 6µm hence giving a 962 
multiple cell layer appearance of the single-cell epithelial structure. Note that the hepatocyte-963 
like organoids grow as solid structures, with all cells marked by HNF4α. (G) The level of 964 
Albumin secreted into the supernatant collected after 24 h is significantly higher in embryonic 965 
organoids cultured with hepatocyte-like medium compared to cholangiocyte-like medium. (H) 966 
AFP secretion into the supernatant after 24 h is increased in embryonic organoids cultured with 967 
hepatocyte-like medium compared to cholangiocyte-like medium and to adult ductal liver 968 
organoids. Graphs are mean ± SEM of n≥2 experiments. 969 
 970 
Figure 5: scRNA-seq of hepatoblasts reveals heterogeneity in the hepatoblast population.  971 
(A) Schematic of the experimental approach, briefly bulk (Liv2+) hepatoblasts and Lgr5-GFP 972 
positive (Liv2+ Lgr5-GFP+) hepatoblasts from E10.5 or E13.5 Lgr5-EGFP-IRES-creERT2 973 
embryos were obtained by FACS and were processed for scRNA-seq analysis using the 974 
Smartseq2 protocol. (B) Clustering analysis (louvain clustering) of all cells analysed (653 975 
sorted cells from E10.5 and E13.5 embryos) classified cells into 3 different clusters: a cluster 976 
that exhibits features of hepatoblasts only (HB, blue), a hepatoblast cluster with hepatocyte-977 
like features (Hep, green) and a hepatoblast cluster with cholangiocyte-like features (Chol, 978 
orange). Representative marker genes of each of these three clusters are shown:  Id3 (HB), Ttr 979 
(Hep) and Car2 (Chol). Clusters are represented using tSNE plots. (C) Diffusion pseudotime 980 
analysis of E10.5 and E13.5 cells shows the HB cluster precedes the divergence of the Hep 981 
cluster or Chol cluster and has a higher proportion of cells in G2M phase. Left panel, diffusion 982 
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map showing DC1 and DC2 components; middle panel, diffusion map where the 3 clusters 983 
identified by louvain clustering are shown; right panel, diffusion map showing the cell cycle 984 
phase. Arrows represent the developmental trajectory originating from the HB cluster. (D) Lgr5 985 
transcript levels as determined using single cell sequencing superimposed on the pseudotime 986 
analysis of all cells. (E) Lgr5-GFP+ cells as identified by FACS data superimposed on the 987 
pseudotime analysis of all cells. Note that there are some Lgr5-GFP+ cells that were sorted as 988 
GFP+ but that have down-regulated the Lgr5 transcript (black arrows), indicating that these 989 
are immediate descendants of Lgr5+ cells. (F) Diffusion map showing the cells segregated by 990 
time-point (blue, E10.5; orange, E13.5). Note that cells sorted at E10.5 map to the HB cluster, 991 
the cells moving towards the HB cluster, the Hep cluster and cells located in the Chol cluster. 992 
At E13.5 the sorted cells map to the HB cluster, the cells moving towards the Chol cluster and 993 
the Chol cluster. Sorted cells no longer map to the Hep cluster, which may indicate that 994 
hepatocyte-committed hepatoblasts do not express the Liv2 epitope at E13.5. 995 
 996 
Figure 6: Lgr5+ hepatoblasts are at the apex of the hepatoblast hierarchy. 997 
(A-F) Pregnant females from both, the Lgr5-Cre (Lgr5-IRES-CreERT2) and the ubiquitous Cre 998 
(R26R-CreERT2) were injected at E9.5 or E13.5 of gestation in order to lineage trace the early 999 
hepatoblast pool. (A) Representative images of Confetti-labelled descendants following 1000 
tamoxifen induction to Lgr5-IRES-CreERT2;R26R-Confetti embryos at E9.5 and liver 1001 
collection at P17. Magnified area highlights cholangiocytes (Osteopontin, purple) outlined in 1002 
blue. (B) Schematic displaying the possible outcomes of labelled proportions following lineage 1003 
tracing of Lgr5+ cells at E9.5 depending on where Lgr5+ cells are in the hepatoblast hierarchy 1004 
(indicated with the blue arrow). If E9.5 Lgr5+ hepatoblasts are at the apex of the hepatoblast 1005 
hierarchy, it is expected that their contribution to the postnatal liver will recapitulate the 1006 
homeostatic proportions of hepatocytes and ductal cells (97% vs 3%) as detailed in (Fig. S6D). 1007 
In the left panel, Lgr5+ cells (blue arrow) are not at the apex, hence the homeostatic proportions 1008 
are not achieved. By contrast, in the right panel Lgr5+ cells are at the apex and therefore 1009 
generate the homeostatic proportions. (C) Quantification of labelled epithelial cells following 1010 
induction at E9.5 from Lgr5-IRES-CreERT2 shows that 3.5% ± 0.5% were ductal, which is 1011 
equivalent to the homeostatic proportion of ductal cells in the postnatal liver (None Cre driver). 1012 
In contrast, the proportion of labelled ductal cells using R26R-CreERT2 at E9.5 to drive 1013 
labelling was significantly higher. At E13.5, lineage tracing from the Lgr5-IRES-CreERT2 1014 
allele resulted in no labelled ductal cells, whilst induction from the R26R-CreERT2 allele at 1015 
E13.5 resulted in the homeostatic proportion (mean ± SEM, each data point represents an 1016 
individual liver). Analysis of postnatal livers was conducted at time-points P0-P30; later time-1017 
points were not considered to prevent homeostatic cellular turnover confounding the data. **, 1018 
p<0.01; ****, p<0.0001. (D) Representative images of Confetti-labelled descendants 1019 
following tamoxifen induction of R26R-CreERT2;R26R-Confetti embryos at E9.5 with liver 1020 
collection at P14.  (E) Cumulative distribution of cluster size frequency at P14-P30, comparing 1021 
labelled clusters derived from Lgr5+ cells (Lgr5-IRES-CreERT2) and the bulk population 1022 
(R26R-CreERT2) induced at E9.5 (mean ± SEM, n≥6). Tracing from Lgr5+ cells results in 1023 
larger clusters than tracing from the bulk population (F), suggesting that Lgr5+ cells have 1024 
greater proliferative potential than the bulk population at E9.5 (mean ± SEM). 1025 
 1026 
 27 
Supplementary Fig. 1: Lgr5 labels hepatoblasts from E9.5 to at least E13.5 of liver 1027 
development.  1028 
(A-D) Lgr5-ires-CreERT2hom; R26R-TdTomatohom males were bred with MF1-WT females in 1029 
order to generate the compound mice Lgr5-IRES-CreERT2het;R26R-TdTomatohet. (A) 1030 
Induction of lineage tracing at E9.5 leads to labelled cholangiocytes (co-stained with OPN) and 1031 
hepatocytes (co-stained with Hnf4α) in a liver collected at P30. Magnifications of labelled 1032 
cholangiocytes and hepatocytes are shown in a’) and b’), respectively, upper panels include 1033 
TdTomato signal, lower panels exclude TdTomato signal to clearly demonstrate the type of 1034 
cell labelled. (B) Induction of lineage tracing at E13.5 resulted in hepatocyte progeny only. (C) 1035 
Cre activity was induced at the indicated time-points and livers collected at P30. Expression of 1036 
TdTomato was detected in postnatal livers only if induction was at E9.5 or later, suggesting 1037 
that Lgr5 is expressed in the developing liver from E9.5 onwards. Scale bar = 2mm. (D) 1038 
TdTomato tracing was almost never detected in non-tamoxifen induced controls. Only in one 1039 
mouse we detected <100 cells labelled in the liver. In contrast, the tracing events in the livers 1040 
of the tamoxifen induced embryos was clear with several thousands of cells labelled. Both the 1041 
non-induced and induced livers were collected at P14. This minute number of labelled cells in 1042 
the non-induced livers does not affect our interpretations in the lineage tracing experiments. 1043 
 1044 
Supplementary Fig. 2: Lineage tracing from Lgr5-IRES-CreERT2;R26R-Confetti and 1045 
R26R-Cre;R26R-Confetti mice induced at E9.5.  1046 
(A-C) Lgr5-IRES-CreERT2het;R26R-Confettihet mice were generated by breeding the Lgr5-1047 
IRES-CreERT2hom with the multicolour Confetti reporter R26R-Confettihom and liver tissues 1048 
were collected postnatally. (A) Labelling of the E9.5 embryonic livers of Lgr5-IRES-1049 
CreERT2het;R26R-Confettihet mice results in cells labelled in one of four colours (RFP, YFP, 1050 
mCFP, nGFP). A representative image of a liver section presenting clones in each of the 4 1051 
colours is shown. Tissue was co-stained with Osteopontin to visualize the ductal cells (OPN, 1052 
magenta). Nuclei were counterstained with Hoechst. a’) magnified area showing a red and a 1053 
yellow clone. b’) magnified area showing a mCFP clone. c’) magnified area showing a nGFP 1054 
clone. Note that no merging of clones is observed. (B) Bicolour-merger events, i.e. clones of 1055 
different colours merging, were rarely detected. Representative image of one of the 5 merging 1056 
events observed in the n=3 livers analysed for bipotent clones (n=2, liver_1; n=3, liver_2, n=0, 1057 
liver_3). Example of a merging event between a CFP and GFP clone following induction at 1058 
E9.5 in Lgr5-IRES-CreERT2het;R26R-Confettihet embryos. Graph represents the mean ± SEM 1059 
of the frequency of mergers within the same colour. (C-D) Tracing events from the R26R-1060 
Confetti reporter in combination with the Lgr5-IRES-CreERT2 (C) or R26R-CreERT2 (D) 1061 
driver only occur upon tamoxifen administration and are never found in non-induced mice. 1062 
 1063 
Supplementary Figure 3: Generation of mouse embryonic liver organoids. 1064 
(A-B) Embryonic liver organoids were generated from whole liver tissue obtained from E11.5 1065 
WT embryos dissociated as described in methods. (A) Isolated cells were embedded in Matrigel 1066 
and cultured in our mouse adult ductal liver organoid medium (Huch et al., 2013) containing 1067 
EGF, Noggin, Rspondin1, FGF10, HGF, Nicotinamide (left panel) or in the same medium 1068 
supplemented with 1 nM A8301 and 10 µM Forskolin (optimized Cholangiocyte-like medium, 1069 
right panel) as described in methods. This resulted in an evident increase in the number and 1070 
 28 
size of organoids formed. (B) Isolated cells embedded in Matrigel were also cultured in the 1071 
recently published hepatocyte medium that sustains human embryonic liver growth in vitro 1072 
(Hu et al., 2018). Removal of FGF7 resulted in a significant improvement on the expansion of 1073 
the organoids. For details refer to methods. (C) Comparison of renewal potential between 1074 
embryonic organoids derived from ‘whole liver tissue’ or ‘sorted Lgr5+’cells. We find 1075 
comparable renewal potentials between ‘sorted Lgr5+’ and ‘whole liver tissue’ cholangiocyte-1076 
like organoids. In the case of the hepatocyte-like organoids the ‘whole liver tissue’ cells form 1077 
structures which can be easily passaged (up to P4 to date). Although, the ‘sorted Lgr5+’ cells 1078 
readily form hepatocyte-like organoids and can withstand initial passaging, their viability then 1079 
decreases. (D) Immunofluorescence staining for Ctnnb1 with the ductal marker Krt19 and the 1080 
hepatocyte marker HNF4α in adult ductal liver organoids cultured in our standard organoid 1081 
medium as described in (Huch et al., 2013). These served as positive control for the stainings 1082 
shown in Figure 4. 1083 
 1084 
Supplementary figure 4: Lgr5+ hepatoblast sorting strategy.  1085 
Lgr5-EGFP-IRES-CreERT2het mice were bred with MF1-WT females and embryos collected 1086 
at E10.5 of gestation. WT and Lgr5-EGFP-IRES-CreERT2het littermate embryos were scored 1087 
for the presence of eGFP in the cranial area. Then, embryos were split by genotype and liver 1088 
tissues collected and processed for cell isolation and single cell dissociation. Cells were stained 1089 
with the hepatoblast marker Liv2, the endothelial maker CD31 and pan-haemopoietic marker 1090 
CD45 as described in methods. Sorted cells were obtained following a sequential gating 1091 
strategy where cells were first gated by FSC vs SSC, then FSC vs Pulse width to identify 1092 
singlets and then gated for Liv2+ (bulk hepatoblasts, Liv2+CD31-CD45- (red box)) or 1093 
Liv2+GFP+ (Lgr5+ hepatoblasts, (Liv2+CD31-CD45-GFP+ (blue dashed box))). 1094 
 1095 
Supplementary Figure 5: scRNA-seq of hepatoblasts reveals heterogeneity in the 1096 
hepatoblast population. (A) Heatmap displaying the 30 most differentially expressed genes 1097 
in each cluster as detailed in Supplementary Dataset 1, (colour represents the log-transformed 1098 
number of reads (with an offset of 1), dendograms represent hierarchical clustering of cells). 1099 
(B) Proportion of cells in G2M phase of the cell cycle in the hepatoblast cluster (HB), 1100 
cholangiocyte-like cluster (Chol) and hepatocyte-like cluster (Hep) (mean±95% confidence 1101 
intervals). (C) Histogram of the distribution of Lgr5 counts shows a bimodal distribution. A 1102 
threshold of 10 counts is used to define a cell as Lgr5+ on the transcript level. Using this 1103 
threshold, we find that 2% of the bulk cells at E10.5 are Lgr5+ at the transcript level.(D) 1104 
Heatmap displaying the differentially expressed genes by time-point, (colour represents the 1105 
log-transformed number of reads (with an offset of 1), dendograms represent hierarchical 1106 
clustering of cells). For extended list see Supplementary Dataset 1_S2-S6. 1107 
 1108 
Supplementary Figure 6: Counting of hepatocyte and cholangiocyte cell proportions in 1109 
the homeostatic postnatal liver. (A-C) To determine the homeostatic proportions of 1110 
hepatocytes and cholangiocytes at the different postnatal time-points of interest osteopontin 1111 
(OPN) staining was performed to mark the ductal cells and then the proportion of hepatocytes 1112 
vs cholangiocytes was counted using an automated system. (A) Osteopontin (OPN, purple) 1113 
marks ductal cells in the P14 liver (nuclei are counter stained with Hoechst 33342). 1114 
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Immunofluorescent images were segmented using ilastik-1.2.2 software, machine learning was 1115 
used to train the software to segment cholangiocytes (middle panel), hepatocytes (right panel), 1116 
other cells or background, segmented cells are marked in red). The segmented images were 1117 
then imported into Fiji, a selection was created around the segmented images and overlaid on 1118 
the Hoechst channel. Within the cholangiocyte or hepatocyte selections the number of cells 1119 
were counted using the find maxima function on the Hoechst channel. (B) Magnification of A) 1120 
to show the cells counted (yellow cross-hairs) following segmentation of cholangiocyte and 1121 
hepatocyte cells. Note only epithelial cells are counted, other cells including mesenchymal and 1122 
endothelial cells (a selection are highlighted with red arrows) are not counted. (C) Automated 1123 
counting reveals the homeostatic number of cholangiocytes as a percentage of epithelial cells 1124 
is ~3% at all 3 time-points (P0, P14 and P30) analysed. Graph represents the percentage of 1125 
cholangiocytes within the total epithelial cells counted at the 3 time-points analysed (mean ± 1126 
STDEV).  On average a 3.4% ± 0.6% of epithelial cells of the mouse liver are cholangiocytes, 1127 
this proportion does not change over postnatal days P0 - P30 (mean ± STDEV). Table indicates 1128 
the total number of cells counted and the % of cholangiocytes within these at each of the 3 1129 
time-points analysed. 1130 
  1131 
 30 
Supplementary video S1: Confocal Z-stack video showing co-staining of TdTomato+ 1132 
Lgr5+ descendants with the endothelial marker VEGFR3 at E11.5 following induction at 1133 
E9.5 1134 
 1135 
Supplementary video S2: Confocal Z-stack video of a bipotent Lgr5 clone derived from 1136 
an Lgr5-IRES-creERT2;R26R-Confetti embryo injected at E9.5 1137 
 1138 
Supplementary dataset 1: scRNA-seq gene lists 1139 
 1140 
Supplementary dataset 2: Tracing counts used for the analysis 1141 
 1142 
Supplementary dataset 3: List of material and reagents used in the manuscript  1143 
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Figure 1: Lgr5 expression marks cells with hepatoblast features in the developing liver.
(A-C) Lgr5-IRES-CreERT2hom;R26R-TdTomatohom males were bred with MF1-WT females in order to generate 
Lgr5-IRES-CreERT2het; R26R-TdTomatohet embryos. Administration of tamoxifen to pregnant females at E9.5 leads to activation 
of Cre in Lgr5+ cells and recombination at the ROSA locus to induce expression of TdTomato in E9.5-E10 Lgr5+ cells and their 
progeny. (A) Schematic of experimental approach. Expression of TdTomato can be detected in E11.5 livers following induction at 
E9.5, indicating the presence of Lgr5+ cells in the developing liver at E9.5 (n≥3 independent experiments, n=2 independent 
litters). Representative image of TdTomato epi-fluorescence (red) is shown. Nuclei were counterstained with Hoechst (grey). (B) 
Representative immunofluorescent staining of TdTomato-expressing cells co-stained with the hepatoblast marker AFP (green, 
top panel), endothelial marker VEGFR3 (green, middle top panel), pan-haematopoietic marker CD45 (green, middle bottom 
panel) and the proliferative marker Ki67 (green, bottom panel). (C) Quantification of the immunostainings shown in B. 100% of 
TdTomato+ cells co-express AFP and are negative for endothelial and haematopoietic fate markers (n>30, n=2 independent 
litters). At least half of TdTomato+ cells are proliferative (Ki67+, n>50, n=2 independent litters).
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Figure 2: Lgr5 is a marker of bona fide hepatoblasts in vivo.
(A) Schematic of experimental approach. TdTomato expression was induced at E9.5 and livers collected at the indicated postna-
tal time-points. (B) Lgr5+ progeny (TdTomato+ cells, red) are found distributed along all 3 zones of the liver lobule; the portal triad 
(PT, zone 1), the central vein (CV, zone 3) and the intermediate region (zone 2) at all time-points analysed, up to 12 months after 
birth. In the portal area labelled cells include both hepatocytes and cholangiocytes (Osteopontin, green), indicating that E9.5-E10 
Lgr5+ cells are bona fide hepatoblasts. Right panels represent a magnified area from zone 1.
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Figure 3: E9.5 Lgr5+ hepatoblasts are bipotent.
(A-D) Lgr5-IRES-CreERT2hom mice were mated with multicolour Confetti reporter R26R-Confettihom mice to generate 
Lgr5-IRES-CreERT2het;R26R-Confettihet embryos. Induction with tamoxifen at E9.5 results in Lgr5+ cells and progeny being 
labelled in one of four colours (RFP, YFP, mCFP, nGFP). (A) Schematic of experimental design. Two potential outcomes are 
illustrated; a single Lgr5+ hepatoblast (red circle) is bipotent and gives rise to both hepatocytes (red squares) and cholangiocytes 
(red triangles) or, alternatively, single Lgr5+ hepatoblasts (blue and yellow circles) are unipotent and independently give rise to 
hepatocytes (blue squares) and cholangiocytes (yellow triangles). (B-C) Representative images of P0 Lgr5-IRES-CreERT2het-
;R26R-Confettihet  liver following induction at E9.5. Ductal cells were co-stained with Osteopontin (blue, white arrows). Nuclei 
were stained with Hoechst. (B) Low power magnification of a liver section showing a red and a yellow clone (white arrows). (C) 
Magnification showing that the red clone contains both hepatocytes and cholangiocytes (white arrows).  (D) Pie charts showing 
the total number of clones identified (n=70) and the fraction of these that are located in the portal area (n=26). Note that from the 
total number of clones found in the portal area, half of them (n=13) contained both hepatocytes and cholangiocytes of the same 
colour. At the induction dose used, the frequency of mergers of clusters of the same colour is less than 3.6 ± 1.9% for all colours, 
(see Supplementary Fig. 2B), which confirms that at least 12 of the 13 bipotent clones identified arise from a single Lgr5+ cell, 
demonstrating that Lgr5+ cells are bipotent at E9.5. Experiments were performed in n=3 embryos.  
Total=70
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 Figure 4: Lgr5+ embryonic liver cells form both cholangiocyte-like and hepatocyte-like organoids  







































Figure 4: Lgr5+ embryonic liver cells form both cholangiocyte-like and hepatocyte-like organoids in vitro
(A) Section of an E10.5 liver showing co-labelling of Lgr5-GFP+ cells (green) with the liver progenitor marker Liv2 (purple). Nuclei 
were counterstained with Hoechst. (B-H) Embryonic liver organoids were generated from sorted Lgr5-GFP+ hepatoblasts 
isolated from E10.5-E12.5 Lgr5-EGFP-IRES-creERT2 livers. (B) Schematic of the experimental approach. (C-D) Representative 
image of a mouse embryo liver organoid derived from a single Lgr5-GFP+ cell and cultured in (C) cholangiocyte-like medium or 
(D) hepatocyte-like medium (Day 0 & 2 scale bar =10µm). Note the hepatocyte morphology of cells in the organoids grown in 
hepatocyte-like medium. (E) Expression of the ductal marker Krt19 is predominantly detected in embryonic organoids grown in 
cholangiocyte-like medium and in control adult liver organoids, while the hepatocyte marker Albumin (Alb) is detected at much 
higher levels in embryonic cells cultured in hepatocyte-like medium. (F) Immunofluorescence staining of organoids derived from 
Lgr5-GFP+ embryonic liver cells shows clear expression of either the ductal marker Krt19 in organoids grown in 
cholangiocyte-like medium (left panel) or the hepatocyte marker HNF4α in organoids grown in hepatocyte-like medium (right 
panel), (nuclei counterstained with Hoechst, membranes labelled with Ctnnb1). The image of embryonic organoids grown in 
cholangiocyte-like medium represents a projection of 6µm hence giving a multiple cell layer appearance of the single-cell 
epithelial structure. Note that the hepatocyte-like organoids grow as solid structures, with all cells marked by HNF4α. (G) The 
level of Albumin secreted into the supernatant collected after 24 h is significantly higher in embryonic organoids cultured with 
hepatocyte-like medium compared to cholangiocyte-like medium. (H) AFP secretion into the supernatant after 24 h is increased 
in embryonic organoids cultured with hepatocyte-like medium compared to cholangiocyte-like medium and to adult liver 
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Figure 5: scRNAseq of hepatoblasts reveals heterogeneity in the hepatoblast population. 
(A) Schematic of the experimental approach, briefly bulk (Liv2+) hepatoblasts and Lgr5-GFP positive (Liv2+ Lgr5-GFP+) hepato-
blasts from E10.5 or E13.5 Lgr5-EGFP-IRES-creERT2 embryos were obtained by FACS and were processed for scRNAseq 
analysis using the Smartseq2 protocol. (B) Clustering analysis (louvain clustering) of all cells analysed (653 sorted cells from 
E10.5 and E13.5 embryos) classified cells into 3 different clusters: a cluster that exhibits features of hepatoblasts only (HB, blue), 
a hepatoblast cluster with hepatocyte-like features (Hep, green) and a hepatoblast cluster with cholangiocyte-like features (Chol, 
orange). Representative marker genes of each of these three clusters are shown:  Id3 (HB), Ttr (Hep) and Car2 (Chol). Clusters 
are represented using tSNE plots. (C) Diffusion pseudotime analysis of E10.5 and E13.5 cells shows the HB cluster precedes 
the divergence of the Hep cluster or Chol cluster and has a higher proportion of cells in G2M phase. Left panel, diffusion map 
showing DC1 and DC2 components; middle panel, diffusion map where the 3 clusters identified by louvain clustering are shown; 
right panel, diffusion map showing the cell cycle phase. Arrows represent the developmental trajectory originating from the HB 
cluster. (D) Lgr5 transcript levels as determined using single cell sequencing superimposed on the pseudotime analysis of all 
cells. (E) Lgr5-GFP+ cells as identified by FACS data superimposed on the pseudotime analysis of all cells. Note that there are 
some Lgr5-GFP+ cells that were sorted as GFP+ but that have down-regulated the Lgr5 transcript (black arrows), indicating that 
these are immediate descendants of Lgr5+ cells. (F) Diffusion map showing the cells segregated by time point (blue, E10.5; 
orange, E13.5). Note that cells sorted at E10.5 map to the HB cluster, the cells moving towards the HB cluster, the Hep cluster 
and cells located in the Chol cluster. At E13.5 the sorted cells map to the HB cluster, the cells moving towards the Chol cluster 
and the Chol cluster. Sorted cells no longer map to the Hep cluster, which may indicate that hepatocyte-committed hepatoblasts 
do not express the Liv2 epitope at E13.5.
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Figure 6: Lgr5+ hepatoblasts are at the apex of the hepatoblast hierarchy.
(A-F) Pregnant females from both, the Lgr5-Cre (Lgr5-IRES-CreERT2) and the ubiquitous Cre (R26R-CreERT2) were injected 
at E9.5 or E13.5 of gestation in order to lineage trace the early hepatoblast pool. (A) Representative images of Confetti-labelled 
descendants following tamoxifen induction to Lgr5-IRES-CreERT2;R26R-Confetti embryos at E9.5 and liver collection at P17. 
Magnified area highlights cholangiocytes (Osteopontin, purple) outlined in blue. (B) Schematic displaying the possible outcomes 
of labelled proportions following lineage tracing of Lgr5+ cells at E9.5 depending on where Lgr5+ cells are in the hepatoblast 
hierarchy (indicated with the blue arrow). If E9.5 Lgr5+ hepatoblasts are at the apex of the hepatoblast hierarchy, it is expected 
that their contribution to the postnatal liver will recapitulate the homeostatic proportions of hepatocytes and ductal cells (97% vs 
3%) as detailed in (Fig. S6D). In the left panel, Lgr5+ cells (blue arrow) are not at the apex, hence the homeostatic proportions 
are not achieved. By contrast, in the right panel Lgr5+ cells are at the apex and therefore generate the homeostatic proportions. 
(C) Quantification of labelled epithelial cells following induction at E9.5 from Lgr5-IRES-CreERT2 shows that 3.5% ± 0.5% were 
ductal, which is equivalent to the homeostatic proportion of ductal cells in the postnatal liver (None Cre driver). In contrast, the 
proportion of labelled ductal cells using R26R-CreERT2 at E9.5 to drive labelling was significantly higher. At E13.5, lineage 
tracing from the Lgr5-IRES-CreERT2 allele resulted in no labelled ductal cells, whilst induction from the R26R-CreERT2 allele at 
E13.5 resulted in the homeostatic proportion (mean ± SEM, each data point represents an individual liver). Analysis of postnatal 
livers was conducted at timepoints P0-P30; later time points were not considered to prevent homeostatic cellular turnover 
confounding the data. **, p<0.01; ****, p<0.0001. (D) Representative images of Confetti-labelled descendants following tamox-
ifen induction of R26R-CreERT2;R26R-Confetti embryos at E9.5 with liver collection at P14.  (E) Cumulative distribution of 
cluster size frequency at P14-P30, comparing labelled clusters derived from Lgr5+ cells (Lgr5-IRES-CreERT2) and the bulk 
population (R26R-CreERT2) induced at E9.5 (mean ± SEM, n≥6). Tracing from Lgr5+ cells results in larger clusters than tracing 
from the bulk population (F), suggesting that Lgr5+ cells have greater proliferative potential than the bulk population at E9.5 
(mean ± SEM).
Supplementary Figure 1: Lgr5 labels hepatoblasts from E9.5 to at least E13.5 of liver development.
(A-D) Lgr5-ires-CreERT2hom; R26R-TdTomatohom males were bred with MF1-WT females in order to generate the 
compound mice Lgr5-IRES-CreERT2het;R26R-TdTomatohet. (A) Induction of lineage tracing at E9.5 leads to labelled 
cholangiocytes (co-stained with OPN) and hepatocytes (co-stained with Hnf4α) in a liver collected at P30. 
Magnifications of labelled cholangiocytes and hepatocytes are shown in a’) and b’), respectively, upper panels include 
TdTomato signal, lower panels exclude TdTomato signal to clearly demonstrate the type of cell labelled. (B) Induction 
of lineage tracing at E13.5 resulted in hepatocyte progeny only. (C) Cre activity was induced at the indicated timepoints 
and livers collected at P30. Expression of TdTomato was detected in postnatal livers only if induction was at E9.5 or 
later, suggesting that Lgr5 is expressed in the developing liver from E9.5 onwards. Scale bar = 2mm. (D) TdTomato 
tracing was almost never detected in non-tamoxifen induced controls. Only in one mouse we detected <100 cells 
labelled in the liver. In contrast, the tracing events in the livers of the tamoxifen induced embryos was clear with several 
thousands of cells labelled. Both the non-induced and induced livers were collected at P14. This minute number of 
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Supplementary Figure 2: Lineage tracing from Lgr5-ires-creERT2;R26R-confetti and R26RCre;R26R-confetti mice 
induced at E9.5. 
(A-C) Lgr5-IRES-CreERT2het;R26R-Confettihet mice were generated by breeding the Lgr5-IRES-CreERT2hom with the 
multicolour Confetti reporter R26R-Confettihom and liver tissues were collected postnatally. (A) Labelling of the E9.5 
embryonic livers of Lgr5-IRES-CreERT2het;R26R-Confettihet mice results in cells labelled in one of four colours (RFP, YFP, 
mCFP, nGFP). A representative image of a liver section presenting clones in each of the 4 colours is shown. Tissue was 
co-stained with Osteopontin to visualize the ductal cells (OPN, magenta). Nuclei were counterstained with Hoechst. a’) 
magnified area showing a red and a yellow clone. b’) magnified area showing a mCFP clone. c’) magnified area showing a 
nGFP clone. Note that no merging of clones is observed. (B) Bicolour-merger events, i.e. clones of different colours merging, 
were rarely detected. Representative image of one of the 5 merging events observed in the n=3 livers analysed for bipotent 
clones (n=2, liver_1; n=3, liver_2, n=0, liver_3). Example of a merging event between a CFP and GFP clone following 
induction at E9.5 in Lgr5-IRES-CreERT2het;R26R-Confettihet embryos. Graph represents the mean ± SEM of the frequency of 
mergers within the same colour. (C-D) Tracing events from the R26R-Confetti reporter in combination with the 





























































Mouse media used Huch et al., 2013b
Hepatocyte-like media + FGF7
Hepatocyte-like media - no FGF7
Cholangiocyte-like media
(optimised with additon of TGFb inhibitor and Forskolin)
Supplementary Figure 3: Generation of mouse embryonic liver organoids. 
(A-B) Embryonic liver organoids were generated from whole liver tissue obtained from E11.5 WT embryos dissociated as 
described in methods. (A) Isolated cells were embedded in Matrigel and cultured in our mouse adult ductal liver organoid medium 
(Huch et al., 2013) containing EGF, Noggin, Rspondin1, FGF10, HGF, Nicotinamide (left panel) or in the same medium 
supplemented with 1 nM A8301 and 10 µM Forskolin (optimized Cholangiocyte-like medium, right panel) as described in 
methods. This resulted in an evident increase in the number and size of organoids formed. (B) Isolated cells embedded in 
Matrigel were also cultured in the recently published hepatocyte medium that sustains human embryonic liver growth in vitro (Hu 
et al., 2018). Removal of FGF7 resulted in a significant improvement on the expansion of the organoids. For details refer to 
methods. (C) Comparison of renewal potential between embryonic organoids derived from ‘whole liver tissue’ or ‘sorted 
Lgr5+’cells. We find comparable renewal potentials between ‘sorted Lgr5+’ and ‘whole liver tissue’ cholangiocyte-like organoids. 
In the case of the hepatocyte-like organoids the ‘whole liver tissue’ cells form structures which can be easily passaged (up to P4 
to date). Although, the ‘sorted Lgr5+’ cells readily form hepatocyte-like organoids and can withstand initial passaging, their 
viability then decreases. (D) Immunofluorescence staining for Ctnnb1 with the ductal marker Krt19 and the hepatocyte marker 
HNF4α in adult ductal liver organoids cultured in our standard organoid medium as described in (Huch et al., 2013). These 
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SUPPLEMENTARY Fig. 4
Supplementary Figure 4: Lgr5+ hepatoblast sorting strategy.
Lgr5-EGFP-IRES-CreERT2het mice were bred with MF1-WT females and embryos collected at E10.5 of gestation. WT and 
Lgr5-EGFP-IRES-CreERT2het littermate embryos were scored for the presence of eGFP in the cranial area. Then, embryos 
were split by genotype and liver tissues collected and processed for cell isolation and single cell dissociation. Cells were 
stained with the hepatoblast marker Liv2, the endothelial maker CD31 and pan-haemopoietic marker CD45 as described in 
methods. Sorted cells were obtained following a sequential gating strategy where cells were first gated by FSC vs SSC, then 
FSC vs Pulse width to identify singlets and then gated for Liv2+ (bulk hepatoblasts, Liv2+CD31-CD45- (red box)) or 
Liv2+GFP+ (Lgr5+ hepatoblasts, (Liv2+CD31-CD45-GFP+ (blue dashed box))).
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Supplementary Figure 5: scRNA-seq of hepatoblasts reveals heterogeneity in the hepatoblast population. 
(A) Heatmap displaying the 30 most differentially expressed genes in each cluster as detailed in Supplementary Dataset 1, 
(colour represents the log-transformed number of reads (with an offset of 1), dendograms represent hierarchical clustering of 
cells). (B) Proportion of cells in G2M phase of the cell cycle in the hepatoblast cluster (HB), cholangiocyte-like cluster (Chol) 
and hepatocyte-like cluster (Hep) (mean±95% confidence intervals). (C) Histogram of the distribution of Lgr5 counts shows a 
bimodal distribution. A threshold of 10 counts is used to define a cell as Lgr5+ on the transcript level. Using this threshold, we 
find that 2% of the bulk cells at E10.5 are Lgr5+ at the transcript level.(D) Heatmap displaying the differentially expressed 
genes by time point, (colour represents the log-transformed number of reads (with an offset of 1), dendograms represent 
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P0      43443  3.72%
P14      62248   3.55%
P30      40019  2.91%
Supplementary Figure 6: Counting of hepatocyte and cholangiocyte cell proportions in the 
homeostatic postnatal liver. (A-C) To determine the homeostatic proportions of hepatocytes and cholangiocytes at 
the different postnatal time points of interest osteopontin (OPN) staining was performed to mark the ductal cells and 
then the proportion of hepatocytes vs cholangiocytes was counted using an automated system. (A) Osteopontin (OPN, 
purple) marks ductal cells in the P14 liver (nuclei are counter stained with Hoechst 33342). Immunofluorescent images 
were segmented using ilastik-1.2.2 software, machine learning was used to train the software to segment 
cholangiocytes (middle panel), hepatocytes (right panel), other cells or background, segmented cells are marked in 
red). The segmented images were then imported into Fiji, a selection was created around the segmented images and 
overlaid on the Hoechst channel. Within the cholangiocyte or hepatocyte selections the number of cells were counted 
using the find maxima function on the Hoechst channel. (B) Magnification of A) to show the cells counted (yellow 
cross-hairs) following segmentation of cholangiocyte and hepatocyte cells. Note only epithelial cells are counted, other 
cells including mesenchymal and endothelial cells (a selection are highlighted with red arrows) are not counted. (C) 
Automated counting reveals the homeostatic number of cholangiocytes as a percentage of epithelial cells is ~3% at all 
3 time points (P0, P14 and P30) analysed. Graph represents the percentage of cholangiocytes within the total epithelial 
cells counted at the 3 time points analysed (mean ± STDEV).  On average a 3.4% ± 0.6% of epithelial cells of the mouse 
liver are cholangiocytes, this proportion does not change over postnatal days P0 - P30 (mean ± STDEV). Table indicates 
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